DSGN Design Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1807120 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-9.8%
TTM EPS YoY-0.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-36.9%
ROA-34.6%
ROIC (approx.)-35.0%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets6.7%
Debt / equity0.00x
Current ratio16.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| R&D expense | $16.93M | $16.39M | $14.38M | $13.43M | $14.59M | $15.74M | $15.38M | $12.16M |
| SG&A expense | $5.30M | $5.79M | $5.33M | $4.74M | $4.72M | $5.83M | $5.04M | $4.54M |
| Operating income | -$22.23M | -$22.18M | -$19.71M | -$18.17M | -$19.31M | -$21.57M | -$20.42M | -$16.69M |
| Net income | -$20.29M | -$20.16M | -$17.64M | -$16.00M | -$17.00M | -$19.08M | -$17.71M | -$13.65M |
| EBITDA | -$22.09M | -$22.03M | -$19.55M | -$18.01M | -$19.16M | -$21.42M | -$20.26M | -$16.55M |
| EPS (basic) | -0.32 | -0.32 | -0.29 | — | -0.30 | -0.34 | -0.31 | — |
| EPS (diluted) | -0.32 | -0.32 | -0.29 | — | -0.30 | -0.34 | -0.31 | — |
| Weighted avg. shares (diluted) | 63.04M | 62.51M | 61.43M | — | 56.95M | 56.86M | 56.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $15.25M | $12.91M | $12.77M | $16.86M | $15.09M | $19.70M | $13.67M | $22.56M |
| Short-term investments | $193.36M | $194.49M | $210.05M | $202.99M | $190.88M | $196.57M | $216.01M | $222.91M |
| Current assets | $213.96M | $212.01M | $227.05M | $223.78M | $209.03M | $219.79M | $233.64M | $248.04M |
| PP&E, net | $573,000 | $694,000 | $824,000 | $981,000 | $1.10M | $1.26M | $1.38M | $1.41M |
| Total assets | $216.81M | $215.13M | $230.44M | $226.20M | $211.77M | $222.89M | $237.47M | $252.09M |
| Current liabilities | $12.75M | $11.24M | $10.19M | $13.05M | $11.17M | $8.75M | $8.24M | $8.46M |
| Total liabilities | $14.61M | $13.27M | $12.39M | $13.70M | $12.05M | $9.85M | $9.56M | $10.00M |
| Shareholders' equity | $202.20M | $201.86M | $218.05M | $212.50M | $199.72M | $213.04M | $227.92M | $242.10M |
| Shares outstanding | 63.79M | 62.58M | 62.44M | 60.40M | 56.96M | 56.95M | 56.77M | 56.75M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.38M | -$15.52M | -$16.43M | -$11.97M | -$11.16M | -$14.44M | -$16.79M | -$9.86M |
| Capital expenditure | $15,000 | $21,000 | $0 | $34,000 | $0 | $87,000 | $72,000 | $0 |
| Free cash flow | -$15.39M | -$15.54M | -$16.43M | -$12.00M | -$11.16M | -$14.53M | -$16.86M | -$9.86M |
| Investing cash flow | $189,000 | $15.06M | -$7.59M | -$11.58M | $6.51M | $20.12M | $7.87M | $1.83M |
| Financing cash flow | $17.53M | $605,000 | $19.93M | $25.32M | $37,000 | $361,000 | $23,000 | $263,000 |
| Depreciation & amortization | $136,000 | $151,000 | $157,000 | $156,000 | $155,000 | $152,000 | $159,000 | $149,000 |
| Stock-based compensation | $4.05M | $3.87M | $3.92M | $3.44M | $3.59M | $3.98M | $3.54M | $3.47M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.